Adaptive clinical trial design with delayed treatment effects using elicited prior distributions
结合专家先验的延迟治疗效应自适应临床试验设计
Clinical trials with time-to-event endpoints, such as overall survival (OS) or progression-free survival (PFS), are fundamental for evaluating new treatments, particularly in immuno-oncology. However, modern therapies, such as immunotherapies and targeted treatments, often exhibit delayed effects that challenge traditional trial designs. These delayed effects violate the proportional hazards assumption, which underpins standard statistical methods like the Cox proportional…